Section of Hematology / Oncology
Professor of Medicine
Director, Gastrointestinal Oncology; Director, Mesothelioma Program
Referring Physician Access Line: 1-877-DOM-2730
|MD||1989||State University of New York||
|Residency||1991||University of California Los Angeles||Internal Medicine
|Residency||1992||Montefiore Medical Center||Internal Medicine
|Fellowship||1995||Memorial Sloan-Kettering Cancer Center||Hematology/Oncology
Dr. Kindler's research focuses on new drug development for the treatment of malignant mesothelioma, advanced pancreatic cancer and other gastrointestinal malignancies. She designs and conducts clinical trials of novel agents, including angiogenesis inhibitors and other targeted drugs, for patients with these cancers. She is the chair of the Mesothelioma Subcommittee of the Cancer and Leukemia Group B, a multicenter research organization funded by the National Cancer Institute to conduct clinical trials in malignant mesothelioma and other cancers.
Pancreatic Cancer, malignant mesothelioma, colorectal cancer, gastrointestinal stromal tumors (GIST), hepatobiliary cancers.
- Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR. Weekly, high-dose paclitaxel in advanced lung carcinoma: A phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer 97:2480-2486, 2003.
- Kindler HL, Avadhani A, Mani S, Vokes EE. A phase II trial of 9-Aminocamptothecin administered as a 120-hour continuous infusion in patients with advanced gastric cancer. Investigational New Drugs 22:323-7, 2004.
- Otterson GA, Herndon JE II, Watson D, Terrenoire J, Green MR, Kindler HL. Capecitabine in Malignant Mesothelioma: A Phase II Trial by the Cancer and Leukemia Group B. Lung Cancer, 44:251-259, 2004.
- Armato SG III, Oxnard GR, MacMahon H, Vogelzang NJ, Kindler HL, Kocherginsky M, Starkey A. Measurement of mesothelioma on thoracic CT scans: A comparison of manual and computer-assisted techniques. Medical Physics 31(5): 1105-1115, 2004.
- Eng C, Kindler HL, Nattam S, Ansari RH, Kasza K, Wade-Oliver K, Vokes EE. Phase II trial of the epothilone analogue BMS-247550 in patients with advanced colorectal cancer. Annals of Oncology, 15: 928-932, 2004.